Multiple Sclerosis (MS) Drug Market

FierceBiotech  Apr 15  Comment 
Biogen's latest treatment for multiple sclerosis helped repair damaged nerve tissue in a Phase II study, an incremental victory for a novel therapy that has a long way to go.
Forbes  Apr 14  Comment 
Results from using Biogen’s experimental nerve repair drug in a disease of the eye were “mildly encouraging,” experts say, keeping alive the hope that the medicine might work in multiple sclerosis.
FiercePharma  Apr 1  Comment 
Teva Pharmaceutical Industries is facing U.S. allegations that it used kickbacks, disguised as speaking fees, to persuade doctors to boost prescriptions of its multiple sclerosis drug Copaxone and Parkinson's med Azilect.
Benzinga  Apr 1  Comment 
Receptos, Inc. (Nasdaq: RCPT) announced today that the Company has completed enrollment in the RADIANCE Phase 3 trial of ozanimod (formerly RPC1063) in patients with Relapsing Multiple Sclerosis (RMS). The trial was over-enrolled by approximately...
Forbes  Mar 24  Comment 
In the old days, blockbuster drugs were moderately expensive pills taken by hundreds of thousands of patients. Think blood pressure, cholesterol and diabetes pills. But today, many blockbusters are designed to target much less common diseases,...
Reuters  Mar 23  Comment 
Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.
Motley Fool  Mar 8  Comment 
Despite plenty of research dollars being spent, little is still known about the root causes of multiple sclerosis. That's why this latest study is so encouraging for a select group of MS patients, as it may one day lead to a cure.
Benzinga  Feb 27  Comment 
Receptos Inc (NASDAQ: RCPT) gained more than 2 percent after its chief executive said recent data on a promising colitis drug candidate are "as good as it gets." After popping about 2 percent, shares of the drug development company changed...
FierceBiotech  Feb 23  Comment 
After seeing its reputation as a leader in multiple sclerosis erode over recent years, Merck KGaA has decided to carve back the number of staffers working in preclinical R&D in the field.
GenEng News  Feb 18  Comment 
Researchers at the Toronto-based Center for Addiction and Mental Health (CAMH) say they have discovered a promising new approach to treat multiple sclerosis (MS). In a new study, they've identified a previously unknown change in the spinal cord...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki